Small particle size

Because of their small particle size (20-100 nm), DLIFT-LS are suitable as intravenous delivery carriers, expected to exhibit an  in vivo EPR behavior similar to that of liposomes


Solubilization of lipophilic drugs

Due to the presence of large lipophilic/amphiphilic domains within their structures, DLIFT-LS have an excellent capacity for the solubilization of lipophilic/amphiphilic drug molecules.


Stealth behavior

Because DLIFT-LS usually contain significant quantities of PEGylated surfactants, they are expected to display the shared “stealth” behavior of PEGylated nanoparticles.


No need for high shear equipment

DLIFT-LS form spontaneously or with gentle mixing. Therefore, only conventional mixing equipment is needed for their manufacturing


Can be filtered or heat sterilized

DLIFT-LS can easily be filtered through 0.22 µm filter. During
heat sterilization, phase separation may occur, but DLIFT-LS should return to their original state when cooling to ambient temperature



Dilutability uniquely distinguishes DLIFT-LS from other microemulsion systems.


Long term storage at 4oC

A broad temperature stability range (4-50oC) allows the DLIFT-LS to be stored long-term at 4oC


Possible enhanced fusion with cell membrane

Because of their LIFT and small particle size, the internalization of DLIFT-LS nanodroplets  by target cancer cells may be further facilitated  by fusion with cancer cell membrane


Antibody/Ligand Insertion

Insertion of a targeting antibody or ligand into the surface of the DLIFT-LS can be accomplished  as a last step during their preparation

Table 1: Attributes of DLIFT-LS as a tumor targeting platform